Results 11 to 20 of about 354 (165)
Gut and obesity/metabolic disease: Focus on microbiota metabolites
MedComm, Volume 3, Issue 3, September 2022., 2022 The beneficial and negative metabolites produced by gut microbiota. The gut microbiota produces all kinds of beneficial or negative metabolites and directly affects the intestinal barrier and gut hormone (GLP‐1 and PYY) release. After entering circulation, those metabolites regulate satiety, insulin release, adipose tissue function, and systemic ...
Ke Lin, Lixin Zhu, Li Yang
wiley +1 more source
NMR in Biomedicine, Volume 34, Issue 4, April 2021., 2021 Glucose metabolism is decreased in the diabetic heart. Meldonium may provide a route to counteract this by reducing L‐carnitine levels and decreasing the uptake of fatty acids into the mitochondria, resulting in improved cardiac glucose utilization. Hyperpolarized magnetic resonance has revealed that meldonium treatment elevated pyruvate dehydrogenase ...
Dragana Savic +7 more
wiley +1 more source
ChemMedChem, Volume 15, Issue 13, Page 1139-1149, July 3, 2020., 2020 Sights on a new target: A concise synthesis of C‐3‐substituted pyridine‐2,4‐dicarboxylic acid (2,4‐PDCA) derivatives is reported. The derivatives are potent inhibitors of the human 2‐oxoglutarate‐dependent oxygenase aspartate/asparagine‐β‐hydroxylase (AspH), which is a potential medicinal chemistry target for cancer therapy.
Lennart Brewitz +5 more
wiley +1 more source
Кардиоваскулярная терапия и профилактика, 2013 The paper focuses on cytoprotective and additional effects of mildronate. The emphasis is on the latest original research evidence on mildronate effects in the settings of cardiovascular and cerebral ischemia.
I. G. Gordeev, E. O. Taratukhin
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study the effect of treatment with metabolic corrector mildronate on lipid profile, inflammatory factors and endothelium function in patients with ischemic heart disease (IHD).Material and methods.
I. V. Sergienko +6 more
doaj +3 more sources
Metabolic (cytoprotective) therapy of menopausal disturbances
Кардиоваскулярная терапия и профилактика, 2011 The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of ...
S. N. Tolstov, V. B. Mychka
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2016 Aim. To study effect of mildronate on stream-dependent vasodilation in patients with chronic heart failure (CHF).Material and methods. 30 patients with CHF taking standard therapy (diuretic, ACE inhibitor, β- blocker) as well as 30 healthy volunteers ...
L. G. Voronkov +2 more
doaj +1 more source
Кардиоваскулярная терапия и профилактика, 2012 Aim. To compare the effects of Mildronate and hormone replacement therapy (HRT) with estradiol (1 mg) and drospirenone, DSPR (2 mg) on circadian blood pressure (BP) profile, arterial structure and function, and vascular stiffness parameters in women with
S. N. Tolstov +4 more
doaj +1 more source
EFFECTS OF THE DRUG MILDRONATE
, 2023 Mildronate (3-(2,2,2-trimethylhydrazine) propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed in the Latvian Institute of Organic Synthesis. Mildronate was designed as a promising inhibitor of carnitine biosynthesis aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic ...
openaire +1 more source
Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives
Кардиоваскулярная терапия и профилактика, 2012 The review discusses the benefits and various practical aspects of the new cardioprotector mildronate use in cardiology. The latest evidence on the mildronate role in complex therapy of patients with stable angina, or patients in the rehabilitation ...
V. P. Mikhin +3 more
doaj +1 more source